Literature DB >> 25044277

The miR-137 schizophrenia susceptibility variant rs1625579 does not predict variability in brain volume in a sample of schizophrenic patients and healthy individuals.

Emma J Rose1, Derek W Morris, Ciara Fahey, Dara Cannon, Colm McDonald, Cathy Scanlon, Sinead Kelly, Michael Gill, Aiden Corvin, Gary Donohoe.   

Abstract

The micro RNA 137 (miR-137) variant rs1625579 has been identified as a genome-wide significant risk variant for schizophrenia. miR-137 has an established role in neurodevelopment and may mediate cognitive dysfunction in schizophrenia. This role of miR-137 may be related to changes in brain morphology for risk-related genotypes; however this has not yet been delineated. Here we considered whether rs1625579 genotype was predictive of indices of brain structure in patients with schizophrenia and healthy controls. Structural magnetic resonance imaging (sMRI) data (i.e. 3T T1-TFE or 1.5T T1-MPRAGE) were acquired from 150 healthy controls and 163 schizophrenic patients. Two volumetric analyses that considered the impact of miR-137/rs1625579 genotype were carried out on sMRI data. In the first analysis, voxel based morphometry was employed to consider genotype-related variability in local grey and white matter across the entire brain volume. Our secondary analysis utilized the FIRST protocol in FSL to consider the volume of subcortical structures (i.e. bilateral accumbens, amygdala, caudate, hippocampus, pallidum, putamen and thalamus). Several brain regions in both analyses demonstrated the expected main effect of participant group (i.e. schizophrenics < controls), yet there were no regions where we observed an impact of rs1635579 genotype on brain volume. Our analyses suggest that the mechanism by which miR-137 confers risk for schizophrenia and impacts upon cognitive function may not be mediated by changes in local brain volume. However, it remains to be determined whether or not alternative measures of brain structure are related to these functions of miR-137.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  MIR-137; brain volume; rs1625579; schizophrenia; voxel based morphometry

Mesh:

Substances:

Year:  2014        PMID: 25044277     DOI: 10.1002/ajmg.b.32249

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  9 in total

Review 1.  Heterogeneity and individuality: microRNAs in mental disorders.

Authors:  Leif G Hommers; Katharina Domschke; Jürgen Deckert
Journal:  J Neural Transm (Vienna)       Date:  2014-11-14       Impact factor: 3.575

Review 2.  A comprehensive review of the genetic and biological evidence supports a role for MicroRNA-137 in the etiology of schizophrenia.

Authors:  Kensuke Sakamoto; James J Crowley
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-06-14       Impact factor: 3.568

3.  MIR137HG risk variant rs1625579 genotype is related to corpus callosum volume in schizophrenia.

Authors:  Veena S Patel; Sinead Kelly; Carrie Wright; Cota Navin Gupta; Alejandro Arias-Vasquez; Nora Perrone-Bizzozero; Stefan Ehrlich; Lei Wang; Juan R Bustillo; Derek Morris; Aiden Corvin; Dara M Cannon; Colm McDonald; Gary Donohoe; Vince D Calhoun; Jessica A Turner
Journal:  Neurosci Lett       Date:  2015-06-26       Impact factor: 3.046

4.  A GWAS SNP for Schizophrenia Is Linked to the Internal MIR137 Promoter and Supports Differential Allele-Specific Expression.

Authors:  Alix Warburton; Gerome Breen; Vivien J Bubb; John P Quinn
Journal:  Schizophr Bull       Date:  2015-10-01       Impact factor: 9.306

5.  Genome-Wide Supported Risk Variants in MIR137, CACNA1C, CSMD1, DRD2, and GRM3 Contribute to Schizophrenia Susceptibility in Pakistani Population.

Authors:  Ambrin Fatima; Muhammad Farooq; Uzma Abdullah; Muhammad Tariq; Tanveer Mustafa; Muhammad Iqbal; Niels Tommerup; Shahid Mahmood Baig
Journal:  Psychiatry Investig       Date:  2017-09-11       Impact factor: 2.505

6.  MiR-137-derived polygenic risk: effects on cognitive performance in patients with schizophrenia and controls.

Authors:  D Cosgrove; D Harold; O Mothersill; R Anney; M J Hill; N J Bray; G Blokland; T Petryshen; A Richards; K Mantripragada; M Owen; M C O'Donovan; M Gill; A Corvin; D W Morris; G Donohoe
Journal:  Transl Psychiatry       Date:  2017-01-24       Impact factor: 6.222

Review 7.  Genomic Editing of Non-Coding RNA Genes with CRISPR/Cas9 Ushers in a Potential Novel Approach to Study and Treat Schizophrenia.

Authors:  Chuanjun Zhuo; Weihong Hou; Lirong Hu; Chongguang Lin; Ce Chen; Xiaodong Lin
Journal:  Front Mol Neurosci       Date:  2017-02-03       Impact factor: 5.639

Review 8.  Non-Coding RNA as Novel Players in the Pathophysiology of Schizophrenia.

Authors:  Andrew Gibbons; Madhara Udawela; Brian Dean
Journal:  Noncoding RNA       Date:  2018-04-12

9.  Polymorphisms in MicroRNA Genes Associated with Schizophrenia Susceptibility but Not with Effectiveness of MECT.

Authors:  Danwei Zhang; Huihua Li; Kaimo Ding; Zhen Zhang; Si Luo; Guohai Li
Journal:  Comput Math Methods Med       Date:  2021-12-13       Impact factor: 2.238

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.